NewcelX Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NCEL Nasdaq 2836 www.newcelx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NewcelX Ltd.

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - Jan 12th, 2026 5:00 am
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Jan 5th, 2026 5:00 am
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Dec 11th, 2025 5:00 am
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight - Dec 2nd, 2025 3:31 pm
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Nov 17th, 2025 5:00 am
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - Nov 6th, 2025 5:00 am
NewcelX CEO Issues Letter to Shareholders - Nov 4th, 2025 5:00 am
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. - Nov 3rd, 2025 6:25 am
Owning 58% in NewcelX Ltd. (NASDAQ:NCEL) means that insiders are heavily invested in the company's future - Nov 1st, 2025 7:10 am
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger - Oct 30th, 2025 2:15 pm